3-Methyladenine (3-MA)

For research use only.

Catalog No.S2767 Synonyms: NSC 66389

482 publications

3-Methyladenine (3-MA) Chemical Structure

CAS No. 5142-23-4

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

Size Price Stock Quantity  
USD 70 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's 3-Methyladenine (3-MA) has been cited by 482 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D M4rQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPBcm8{dU1? NHv5U5MzcA>? MnHNSG1UVw>? NGfyRVhz\WS3Y3XzJIdzd3e2aDDpcohq[mm2b4L5JIVn\mWldDDv[kBDTE2F MkfUNlU4OTZ3NkG=
A549  Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:ybVE{dU1? Ml7hNog> NETaSHFFVVOR MWXy[YR2[2W|IHfyc5d1cCCrbnjpZol1d3K7IHXm[oVkfCCxZjDCSG1E NFO1bVkzPTdzNkW2NS=>
95D MVTBdI9xfG:|aYOgRZN{[Xl? NVfvXWJtPW2P MXuybC=> M3[3[WROW09? M3;uPIlvcGmkaYTzJGJFVUNvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aB?= MX6yOVcyPjV4MR?=
A549  MmrzRZBweHSxc3nzJGF{e2G7 Mme0OY1O NUjnVIRQOmh? MnHjSG1UVw>? Mmf5bY5pcWKrdIOgRmROSy2rbnT1Z4VlKGGyb4D0c5Rq[yClZXzsJIRm[XSq MVOyOVcyPjV4MR?=
NBL-W-S  NVTwdVd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7oUoJHOW2P M{KyelZp M1;V[IVvcGGwY3XzJGdCVlRvNkGgeI95cWOrdIm= MlPjNlU{OjN{MkK=
NBL-W-S  MlHRRZBweHSxc3nzJGF{e2G7 M1KxZ|FuVQ>? NW\2XFl2Pmh? M1HhbYlv[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JGdCVlRvNkG= M1vCV|I2OzJ|MkKy
A2780cp  NF3xbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\h[Id3OW2P MUOxbC=> NIjBO3FqdmO{ZXHz[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? M4HXeFI2OzJ{Nkm0
A549  NGHUTnlHfW6ldHnvckBCe3OjeR?= MoTtOY1O MoTJNog> NETuUZJ{fXCycnXzd4V{KFOSQzDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCOQ{OtTWk> MYKyOVI5PTZ{OB?=
H157 M2HQW2Z2dmO2aX;uJGF{e2G7 NETRd442dU1? NHPtclYzcA>? NEe0ZYt{fXCycnXzd4V{KFOSQzDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCOQ{OtTWk> MXqyOVI5PTZ{OB?=
MDR Mnj1RZBweHSxc3nzJGF{e2G7 Mlu3NVBuVQ>? NU\hbnVrPmh? NUKyWJJHe3S{ZX7neIhmdnNidHjlJJBwf2W{IH;mJIFvfGmlYX7j[ZIh\HK3Z4O= MmTYNlUxOTl5MEG=
HT-29  NVHJ[IFvSXCxcITvd4l{KEG|c3H5 Mm\QNY1O M3H3OFQ5cA>? MV7EUXNQ M125WIVvcGGwY3XzJIJwenSnen;tbYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ NFPLfFczPDh2MkG1PC=>
Microglia  MV7BdI9xfG:|aYOgRZN{[Xl? Mm\BOY1O MnvtNlRp M160OIRm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MXyyOFgyQDZyMR?=
A2780cp MlvIRZBweHSxc3nzJGF{e2G7 MonUNk42dU1? Mon0NYg> NIHqUHFl\Eh{Tx?= MnfF[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MXGyOFgyPzl2Nh?=
HepG2 NUXDVZBZTnWwY4Tpc44hSXO|YYm= MmWwOY1O M2\kTVRp MlPGbY5kemWjc3XzJGhNKHKnbHXhd4U> MkPrNlQ4OTN3OEe=
A549 NFjoWXJCeG:ydH;zbZMhSXO|YYm= NWjsUFdvPW2P MV[0PIg> NI[yO4ll\WO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubDDk[YF1cCCjbnSg[ZhxemW|c3nvckBt\X[nbIOgc4Yh[2G|cHHz[U0{NCCEZXPsbY4uOSCjbnSgUGM{NUmL NV;JOYQyOjR5ME[zNFM>
U2OS MXjBdI9xfG:|aYOgRZN{[Xl? M3;qWFExdU1? MknONlRp MVPpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[geIhmKFV{T2OgZ4VtdHNiaX7keYNm\CCkeTDEc5g> M2nwbFI1PjN7MEGz
Saos-2 NELwR2FCeG:ydH;zbZMhSXO|YYm= MUexNI1O M1PsXlI1cA>? M4jNUolvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDv[kB1cGViVULPV{Bk\WyuczDpcoR2[2WmIHL5JGRwgA>? MkjINlQ3OzlyMUO=
A549 MXzBdI9xfG:|aYOgRZN{[Xl? NED6fXUyOG2P NUHBdG1kPDiq NX7lR416[WOlZXzldoF1\XNidHjlJJJm\HWldHnvckBw\iClZXzsJJZq[WKrbHn0fUBqdmS3Y3XkJIJ6KFCWWB?= M3f5TVI1PjJ4N{Ky
HCT116  MmO3RZBweHSxc3nzJGF{e2G7 MkLUOY1O MViyOIg> MnrF[Y5p[W6lZYOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHHwbYdmdmmw NWWxS3A4OjR4Mk[1NlI>
HGC-27 MWTGeY5kfGmxbjDBd5NigQ>? NFSyfokyOG2P MmHrNYg> M1:wcIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBtd3O|IHL5JHJCTDByMTDvdkBOUy1{MkC2 MX:yOFQyPjN2OR?=
U2OS  M3z6[GZ2dmO2aX;uJGF{e2G7 NUPITYZ5OC53L{HtUS=> NWnrcGR6PDiq MV3pcoR2[2W|IIPhcIlvd227Y3nuMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> MXSyOFM2QDN2Mh?=
MG-63 Mkn3SpVv[3Srb36gRZN{[Xl? NXnHdllJOC53L{HtUS=> M2r5ZVQ5cA>? Mlm2bY5lfWOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> NIfTfpIzPDN3OEO0Ni=>
MG-63 NGD5SWhCeG:ydH;zbZMhSXO|YYm= MVOwMlUwOW2P NH;WPIU{Omh? NFO1UZJmdmijbnPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygZZBweHSxc3nz MVeyOFM2QDN2Mh?=
MG-63 NVXZZZZSSXCxcITvd4l{KEG|c3H5 M4jxVFExdU1? M1vTNFEzcA>? NFXCW2tmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? NXH4e2NUOjR|NUizNFE>
NTUB1 MW\BdI9xfG:|aYOgRZN{[Xl? M4\ZbVVuVQ>? MXGxMlVp MmXadI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ NU\jSGVZOjR|NEmxO|Y>
T24 M1XremFxd3C2b4Ppd{BCe3OjeR?= MlrhOY1O NWP3R3NxOS53aB?= NGHTO3hxd3SnboTpZZRmeyClZXzlZ495cWJvaX7keYNm\CCjcH;weI9{cXN? MXqyOFM1QTF5Nh?=
SGC-7901  NGq0b|NCeG:ydH;zbZMhSXO|YYm= MnLiNo1O MYCxbC=> NEfZNZBqdmO{ZXHz[ZMhS0FvNDDpcoR2[2WmIHHwc5B1d3Orcx?= NIfxbnMzPDN{MUO0NC=>
SMMC-7721 MkPxRZBweHSxc3nzJGF{e2G7 MkDnNo1O NInXfZkycA>? M2rzcYlv[3KnYYPld{BESS12IHnu[JVk\WRiYYDvdJRwe2m| M3vrOFI1OzJzM{Sw
ECSCs  M4Xhd2Fxd3C2b4Ppd{BCe3OjeR?= NG\DemsyOG2P NWPTUI9wPGh? NV\udlZr\GWlcnXhd4V{KHKjcHHtfYNqdi22cnXheIVlKGGyb4D0c5Nqew>? NGH3U4wzPDNzOUGwPS=>
MCF-7  MmW0SpVv[3Srb36gRZN{[Xl? NI\DbVEyOG2P NW[yUIFjOjSq MkP6bY5pcWKrdIOgeIhmKGG3dH;wbIFogSCrbnT1Z4VlKGK7IHPo[Y1wfGincnHwfUBlenWpcx?= NV\WOZdMOjR|MUW1O|g>
UOK257 NWDMbo1GSXCxcITvd4l{KEG|c3H5 M1fiXFVuVQ>? NUfLRm9IO2h? M2\SNYVvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB? NV7se3BKOjR|MEW2NFQ>
ACHN-5968 NGDxUI9CeG:ydH;zbZMhSXO|YYm= NX3lSVFNPW2P NFPxXY0{cA>? M4\hPYVvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB? MoHMNlQ{ODV4MES=
Huh7 NWHOd5ZYSXCxcITvd4l{KEG|c3H5 MVSycW0> MkXsNVJp NH\WSWpFVVOR MUnpcohq[mm2czDBXmQ5ODV3LXnu[JVk\WRiY3XscEBl\WG2aB?= NV;udGpDOjR{OUezNFA>
Hep3B M3nPe2Fxd3C2b4Ppd{BCe3OjeR?= NXnRfJhQOm2P MmL6NVJp NGrsOFZFVVOR M4DjXIlvcGmkaYTzJGFbTDhyNUWtbY5lfWOnZDDj[YxtKGSnYYTo NHL1bZEzPDJ7N{OwNC=>
RKO NF7ldYpHfW6ldHnvckBCe3OjeR?= NGq4WI4zdU1? MlG5NYg> NUWwWHFjTE2VTx?= NXXET|gx\W6qYX7j[ZMh[2WubDDk[YF1cCCkeTDn[Yxl[W6jbYnjbY4> NYXzPWduOjR{OUG3O|c>
HepG2 E47 M4LCXmZ2dmO2aX;uJGF{e2G7 MWGyMlVuVQ>? MoX2OFhp NV;OUHFwcW6lcnXhd4V{KHSqZTD0c5hq[2m2eTDv[kBCSSxiQmPPMEBidmRiQ1PsOC=> MoPCNlQzPzN5M{i=
LoVo  NHzhfnpCeG:ydH;zbZMhSXO|YYm= MlLoOY1O MV20PIg> Mln3[Y5p[W6lZYOgSGNCNWmwZIXj[YQh[XCxcITvd4l{Ng>? NF3yb|YzPDJyMUixNi=>
WiDr M{DQSGZ2dmO2aX;uJGF{e2G7 MVyxNI1O MXuxbC=> NWjRO2RFcW6qaXLpeJMhWEOETD3pcoR2[2WmIFzDN{BKUSCneIDy[ZN{cW:w MVKyOFE6ODR6OR?=
H1299  NIXITFVHfW6ldHnvckBCe3OjeR?= Ml;TNVBuVQ>? MmixOIg> NHTuZnlqdmO{ZXHz[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? M{Tvd|I1OTd|MkC4
H460 M1\kcGZ2dmO2aX;uJGF{e2G7 M1\GdVExdU1? MlS5OIg> MWPpcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MoDHNlQyPzN{MEi=
A549 NX61SYxmTnWwY4Tpc44hSXO|YYm= NHvONWIyOG2P NWj2eYYyPGh? NHzuZnJqdmirYnn0d{BifXSxcHjh[5khcW6mdXPl[EBjgSCrcoLh[IlifGmxbh?= M{XlUVI1OTR{N{O1
Hep3B MnPGRZBweHSxc3nzJGF{e2G7 MmW0OY1O M3\K[FI1cA>? MmXxZZR1\W63YYTld{BVVkZvzsGgdJJwfGWldHnvckBi\2GrboP0JJNmenWvIIP0ZZJ3[XSrb36tcYVlcWG2ZXSgZZBweHSxc3nz M2DaeVI1ODZ4Nkmz
SMMC-7721 NF\EUWVCeG:ydH;zbZMhSXO|YYm= MUS1cW0> MoK1NlRp NXPBPHlS[XS2ZX71ZZRmeyCWTl[t{tEheHKxdHXjeIlwdiCjZ3HpcpN1KHOncoXtJJN1[XK4YYTpc44udWWmaXH0[YQh[XCxcITvd4l{ MYGyOFA3PjZ7Mx?=
HO8910 MnzVRZBweHSxc3nzJGF{e2G7 Mm\lNVBuVQ>? M{\qcFEzcA>? NYjYXVBL\W6qYX7j[ZMhSjF7LXnu[JVk\WRiYYDvdJRwe2l? MWmyN|k5OzZzMB?=
MCF7 MVvGeY5kfGmxbjDBd5NigQ>? M4rSSlVuVQ>? MX2yOIg> MYDpcoNz\WG|ZYOgR5VQKGmwZIXj[YQh[2WubDDk[YF1cA>? NIHHWZozOzl4Mk[yPS=>
HONE-1  NFOwNIVHfW6ldHnvckBCe3OjeR?= NUHBOoI2PW2P MmjyNYg> NUHw[2lSemWycnXzd4V{KD[{LX3l[IlifGWmIGLPV{Bxem:mdXP0bY9v NUjaeYFvOjN6OUKzOVg>
HeLa MYLGeY5kfGmxbjDBd5NigQ>? NWro[ZJzOTCvTR?= NWfJSYk4Omh? MX\zeZBxemW|c3XzJGxEOyCLSTDlfJBz\XO|aYPvci=> NUDX[2lSOjN6NkS3N|g>
HepG2 MoHUSpVv[3Srb36gRZN{[Xl? M3zmXVExdU1? M2\HR|I1cA>? M4nnO4lvcGmkaYTzJJNqXEmJQWKtJIFv\CCKQmPTMYlv\HWlZXSgZZV1d3CqYXf5 NH:yN4UzOzhzN{C0NC=>
SH-SY5Y MVPGeY5kfGmxbjDBd5NigQ>? MUSxcW0> M4DLUVI1cA>? MonFbY5pcWKrdIOgeIhmKGG3dH;wbIFogSCrbnT1Z4VlKGK7IGTPR3A> NIruU2kzOzd2M{G0PC=>
SH-SY5Y MWXBdI9xfG:|aYOgRZN{[Xl? M4DYdFVuVQ>? M13yNVFp M3HQV4Fjd2yrc3jld{Bk\Wyjc4Tyc4whdmW3cn;wdo91\WO2aY\lJIVn\mWldB?= MUiyN|YyQTN7NR?=
PC12  NH;6WmdHfW6ldHnvckBCe3OjeR?= MUKxNI1O MXyyOIg> M1XDTJdifGW{ NVjTUI5iyqCrbnjpZol1eyClaIntc5RzgXC|aX6tcIls\SCycn;0[YF{d22jbDDhZ5Rqfmm2eT6= MVqyN|YxOzl5OR?=
OV2008 Mk\FRZBweHSxc3nzJGF{e2G7 M3;3[FVuVQ>? NX3ET2pCOjSq MU\jc453\XK2czDGWHk4OjBid3n0bEBETESSIHnueI8h[W5iYXTkbZRqfmViZX\m[YN1KHSxd3Hy[JMhc2mubHnu[{BwfmG{aXHuJINidmOncjDj[Yxtew>? MWiyN|U6OjJ6MR?=
A2780 NXzv[|BtSXCxcITvd4l{KEG|c3H5 NGTWNIs2dU1? NHLoNVUzPGh? MnrQZ49vfmW{dIOgSnR[PzJyIIfpeIghS0SGUDDpcpRwKGGwIHHk[Il1cX[nIHXm[oVkfCC2b4fhdoR{KGurbHzpcochd3[jcnnhckBk[W6lZYKgZ4VtdHN? M4DuR|I{PTl{Mkix
Saos-2  NHTEUpFCeG:ydH;zbZMhSXO|YYm= M3Tu[VFuVQ>? M17GR|k3cA>? NXjsW49kcW6lcnXhd4V{KGOnbHyg[IVifGhiaX7keYNm\CCkeTDQR3g> NXXiTYVDOjN3NkOxO|E>
1321N1 NUWwRnF5S3m2b4TvfIlkcXS7IFHzd4F6 MoS1OY1O NUjCSFlXOjSq MV7wdo91\WO2czDj[YxtKGGpYXnud5QhWEOQLXnu[JVk\WRidH;4bYNqfHl? MYOyN|UzPTJ4NR?=
SH-SY5Y NH35enREgXSxdH;4bYNqfHliQYPzZZk> M4GwTlVuVQ>? NFu5UnEzPGh? MmnjbY5kemWjc3XzJHBEViC2b4jpZ4l1gQ>? M4rQbFI{PTJ3Mk[1
HT-29  M17xWmZ2dmO2aX;uJGF{e2G7 MVmxcW0> M1\jTVQ5Nzl4aB?= MmjubY5pcWKrdIOgRW1RUyCrbnT1Z4V{KGG3dH;wbIFocWNiY3XscEBl\WG2aB?= NETjdJYzOzVyOEK3Ni=>
OR6 M3fTcGZ2dmO2aX;uJGF{e2G7 MV[xNI1O M4TWOlczcA>? NF7ifYJ{fXCycnXzd4V{KEiFVjDy[ZBtcWOjdHnvckBidmRiZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| NFK5V4EzOzN7NUi3OS=>
Hela  MlzKSpVv[3Srb36gRZN{[Xl? NH6xb|g2dU1? NWTCO5VyOjSq M3HDN4lvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> MoP4NlM{QTV4N{m=
MCF-7  M1TQU2Z2dmO2aX;uJGF{e2G7 NYm1eoxvPW2P MYOyOIg> NV3ufHRjcW6qaXLpeJMhe3Sjco\heIlwdi2rbnT1Z4VlKGG3dH;wbIFogQ>? NUn2PFlpOjN|OUW2O|k>
HUVECs NH63RVZHfW6ldHnvckBCe3OjeR?= M3Poe|NuVQ>? M3rmfVI1cA>? MVvicI9kc3NidHjlJJBzd3SnY4TpeoUh\W[oZXP0JI9nKHKnc4\ldoF1em:uIHL5JIlvcGmkaYTpcoch[XW2b4DoZYd6 NYjRS5pJOjN|NUi5Nlg>
T24 NYS2dFF4TnWwY4Tpc44hSXO|YYm= NELZeXUyOG2P M1Pad|Fp NHjXN4Fz\WS3Y3XzJJRp\SClbHXheoFo\SCxZjDMR|Mh[W[2ZYKgZoFq[2GuaX6geJJm[XSvZX70 M2XXV|I{OzV2MEiw
U251MG  Mn3YSpVv[3Srb36gRZN{[Xl? M3foTlNuVQ>? M4rVZ|Fp M{TNO5N2eHC{ZYPz[ZMhVEN|LVnJJJBzd3SnaX6g[ZhxemW|c3nvci=> NYPIZlV[OjN|M{i2NVg>
GTL-16  MVXBdI9xfG:|aYOgRZN{[Xl? MlzEOY1O MorrNlRp Mnj2doVlfWOnczDj[YxtKH[rYXLpcIl1gSCjczDjc41x[XKnZDD0c{Bk\WyuczD0doVifGWmIIfpeIghVUWWIHnubIljcXSxcoO= NFi2UoUzOzNzM{S5NC=>
T-47D MnzySpVv[3Srb36gRZN{[Xl? NXvxdY9WOTCvTR?= MoTONog> NEftdnFqdmirYnn0d{BifXSxcHjh[5kheHKxY3Xzd{BidmRiaX7jdoVie2W|IILhdIFugWOrbjDpcoR2[2WmIHHwc5B1d3Orcx?= MX6yN|MxODB{Nh?=
PaCa44 MkHqRZBweHSxc3nzJGF{e2G7 NHi1XZEzNjWvTR?= MYWxbC=> MV7y[YR2[2W|wrDn[Y5qeGmwLX3l[IlifGWmIHHwc5B1d3Orcx?= NUjKRoIzOjNzMkSxNVI>
MDA-MB231 NFe5U4xHfW6ldHnvckBCe3OjeR?= MYC1cW0> MlfuNYg> M323eYlv[3KnYYPld{Bz\XO4ZYLheJJwdC2vZXTpZZRm\CClYYPwZZNmKGGldHn2ZZRqd25iYX7kJINmdGxiZHXheIg> M2KxelI{ODh6OEWw
HeLa MlTiRZBweHSxc3nzJGF{e2G7 M{j2cFExdU1? NYLKUGlbOmh? MXnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliY3:teJJm[XSvZX70JJdqfGhiUFXJ MX6yN|AxODF|NR?=
SK-HEP-1 MYHBdI9xfG:|aYOgRZN{[Xl? MmDpNVBuVQ>? Mk\DNYg> MYTwdo91\WO2czDh[4FqdnO2IHH1eI9xcGGpeTDhcoQhcW6mdXPld{BieG:ydH;zbZMhcW5iYoXmZYxqdi22cnXheIVlKGOnbHzz NIDEdZMzOjh3OE[0PS=>
HepG2 NX:5WJlNSXCxcITvd4l{KEG|c3H5 M{\FWFNuVQ>? NVXWfZJjPWh? NVfhTW9qemWmdXPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHFFew>? NUXBRmpxOjJ6M{[1PVU>
MCF-7  MXnGeY5kfGmxbjDBd5NigQ>? MoLYNo1O NWD1OXUxOjSq M{XhO4lvcGmkaYTzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KFSPwrC= Mk\QNlQ6PzB4N{[=
MDA-MB-231 NGnHRo9HfW6ldHnvckBCe3OjeR?= MU[ycW0> NWLuZoJ1OjSq M2TDVYlvcGmkaYTzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KFSPwrC= MYeyOFk4ODZ5Nh?=
MCF-7  MVPGeY5kfGmxbjDBd5NigQ>? NIKyNFUzdU1? Mnq5OFhp M{TIWpBzd22xdHXzJHRONWmwZIXj[YQh[2WubDDk[YF1cA>? NX;mWVVyOjR7N{C2O|Y>
MDA-MB-231 MXjGeY5kfGmxbjDBd5NigQ>? NIXnfY0zdU1? NH\yZWs1QGh? NIn5RWJxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? MViyOFk4ODZ5Nh?=
PANC-1  MV7BdI9xfG:|aYOgRZN{[Xl? M1HLeFFuVQ>? NF7hN3c1QGh? NXfLcWZQTE2VTx?= M1XGNIVvcGGwY3XzJIJwenSnen;tbYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ M1;Xb|I1QDR{MUW4
MDA-MB 231 NEG4OItCeG:ydH;zbZMhSXO|YYm= NWLOTWQ1PW2P NW\4VVNNOC53aB?= M{PYcY1w\HWuYYTld{BVd2OxbXnuxs7DqGmwZIXj[YQh[XCxcITvd4l{ NHXSSpozPDh|MEe4NS=>
Microglia  NIrVV|NCeG:ydH;zbZMhSXO|YYm= Mn34OY1O NH;TZ|EzPGh? MnrB[IVkemWjc3XzJIh6eG:6aXGtbY5lfWOnZDDj[YxtKGSnYYTo NYPDTIc4OjR6MUi2NFE>
A2780cp MVfBdI9xfG:|aYOgRZN{[Xl? MYCyMlVuVQ>? NFjVVVYycA>? NWfBdlZ1\GSKMl:= NHXH[mhmdmijbnPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp M1HucVI1QDF5OUS2
HepG2 M2jERmZ2dmO2aX;uJGF{e2G7 NHjlUpM2dU1? NYq4NZJLPGh? NHq1eVVqdmO{ZXHz[ZMh[2WubIXsZZIhdGW4ZXzzJI9nKEiOwrC= M3rkO|I1PzF|NUi3
U2OS NUeyNoJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2THfFExdU1? NYq4XWJJOjSq NVjPOVc4cW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJIlv\HWlZXSgZpkhTG:6 Mn\mNlQ3OzlyMUO=
HCT116 NXjYSFVOSXCxcITvd4l{KEG|c3H5 M4XyN|VuVQ>? MkLGNlRp NECzclZFVVOR NFXtVZRmdmijbnPld{BieGmpZX7pck1qdmS3Y3XkJINmdGxiZHXheIg> MlHmNlQ3OjZ3MkK=
MCF-7  Mn3CRZBweHSxc3nzJGF{e2G7 MV:wMlFuVQ>? M164elZp NH7LOJFmdmijbnPld{B{cXK2aX7vcE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MljXNlI4PTF7OEm=
PC-3  NHThZo5CeG:ydH;zbZMhSXO|YYm= NXHNVGxZOm2P MmG3Nog> MlLobY5kemWjc3XzJG9TUS2rbnT1Z4VlKGOnbHyg[IVifGh? NVHWfVVwOjJ5NEW1PFA>
U251  NGLlNFhCeG:ydH;zbZMhSXO|YYm= NIPtXZc2dU1? M1zSRlI1cA>? Mo[wbY5kemWjc3XzJHMyNWmwZIXj[YQh[2WubDDk[YF1cA>? M4P2NFIzPTd7N{i4
HeLa  M1\tRWFxd3C2b4Ppd{BCe3OjeR?= MXO1cW0> Ml7xNlRp NXnwVXhjcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBk\WyuIHTlZZRp NXTwWYZrOjJ3NEWxNlg>
A549 MonCSpVv[3Srb36gRZN{[Xl? MmLGNE4ydU1? Mn\QNlRp NFTXeXp{fXCycnXzd4V{KFOXMUGyO|QucW6mdXPl[EBk\WyuIHTlZZRp MoPXNlI1PjZ7NkC=
pDCs MXvGeY5kfGmxbjDBd5NigQ>? M3nIV|ExdU1? MVmwMlVp M4HsXOKhemWmdXPld{B1cGViaX7keYN1cW:wIH;mJGlHVi4QsTDifUB{e1KQQUSw MmrCNlI{QTZ3OUm=
BGC-823 NYLxbZNtTnWwY4Tpc44hSXO|YYm= NXuxdIJFPW2P NHr2dWgzcA>? M4\OfYlvcGmkaYTzJJRp\SC{YYTlJI9nKGG3dH;wbIFocWNiY3XscJM> NUXZS5ozOjJ|MkKxOVI>
U937 NIjhc|BHfW6ldHnvckBCe3OjeR?= MkLNNo1O NXjmS5oxOTKq NUnrUHZV\GWlcnXhd4V{KHSqZTDheZRweGijZ4mgdoF1cW0EoB?= NHvq[VUzOjF3NUG1NC=>
Marc-145 M12wfmZ2dmO2aX;uJGF{e2G7 M33Sb|VuVQ>? NI\QfFkyOi9{ND:zOog> MYXy[YR2[2W|IITo[UBRWlKVVjD0bZRmenNiYX7kJJRp\SCycn;0[YlvKGW6cILld5Nqd25? MlTENlIyOTl7MEC=
HBx  M4W2V2Fxd3C2b4Ppd{BCe3OjeR?= M2XWTVExdU1? M1zFZlQ5cA>? NF7rVYpFVVOR M3XoOolv[3KnYYPld{Bk\WyuIHTlZZRp M4\ERlIzODJyMEe4
MCF-7 MkfHSpVv[3Srb36gRZN{[Xl? MUWxNI1O MUm0PIg> MVXicI9kc3NiYYX0c5Bp[We7IHnu[JVk\WRiYomgZo9zfGW8b33pZi=> MnS1NlE6OzF7M{e=
RMPI8226  M4TsN2Z2dmO2aX;uJGF{e2G7 MVS1cW0> MXSxbC=> NVLz[ZJNe3WycILld5NmeyC2aHWgcIV3\Wxib3[gZZV1d3CqYXf5JJVv\GW{IH71eJJq\W62IHTldIxmfGmxbh?= NVnrb3U3OjF7MUW2NlA>
PC12/TetOn MmrQSpVv[3Srb36gRZN{[Xl? Ml7KNE4yNzGvTR?= MmryNVhp NXXpWlVPdGWjZIOgeI8h|rFvc4nuLHdVMSCjY3P1cZVt[XSrb36sJJRwgGmlaYT5MEBidmRib3zp[49u\XJiZn;ycYF1cW:wwrC= NXP6bpVOOjF7ME[2OVk>
HeLa  MmnYR5l1d3SxeHnjbZR6KEG|c3H5 NXnwNGNiOm2P M4f6UlI1cA>? M1\FcIlvcGmkaYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKHOrbHnibY5qdiC2bzDI[WxiKGOnbHzzMi=> MlfSNlE5PzV|OEW=
Jurkat NYrL[JdxTnWwY4Tpc44hSXO|YYm= M1;p[FExdU1? Ml\5NYg> MmLP[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= NV;4XZc4OjF6NkSwN|c>
K562 NWj1dItPTnWwY4Tpc44hSXO|YYm= MUGxNI1O MkfTNYg> M1L3U4Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzNvSVmgZY5lKHSqZTDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= NFrkS5YzOTh4NECzOy=>
Nara-H M{LOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXTOY1O M3zFTlQ5cA>? MkHw[Y5p[W6lZYOgeIVue2m{b3zpcZV{dWWmaXH0[YQhe3WycILld5Nqd25ib3[gUoFz[S2KIHPlcIwheHKxbHnm[ZJifGmxbh?= MnXPNlE5ODVyM{O=
HUVECs M{K5OGZ2dmO2aX;uJGF{e2G7 NH;KS4syOG2P MYOwMlVp MlTP[IVkemWjc3XzJJRp\SCDR1WtRnNCcW6mdXPl[EBifXSxcHjh[5khdGW4ZR?= NFnKR3IzOTR4OEW5Ni=>
HepG2 M{\ZXWFxd3C2b4Ppd{BCe3OjeR?= MonENo1O NXPlenJyOWh? M1\FZoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJINmdGxiZHXheIg> MWqyNVQ2OzZ7MR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
- Collapse

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
- Collapse
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
- Collapse
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
DMSO 3 mg/mL warmed (20.11 mM)
Ethanol ''4 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389
Smiles CN1C=NC(=N)C2=C1N=CN2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID